AUTHOR=Chen Zhang-Ren , Zhou Ying , Liu Jin , Peng Hong-Wei , Zhou Jian , Zhong Hai-Li , Liu Li-Li , Lai Ming-Fang , Wei Xiao-Hua , Wen Jin-Hua 

TITLE=Pharmacotherapics Advice in Guidelines for COVID-19

JOURNAL=Frontiers in Pharmacology

VOLUME=11

YEAR=2020

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00950

DOI=10.3389/fphar.2020.00950

ISSN=1663-9812

ABSTRACT=<p>Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.</p>